SCLC cell lines have a higher median CHK1 protein and gene expression than NSCLC lines, and the CHK1 inhibitor prexasertib demonstrated strong anti-tumor activity in SCLC cell lines, SCLC syngeneic, genetically-engineered mouse (GEM) and chemo-resistant models (19). Here, CHEK1 is linked to small cell lung carcinoma.